October 13, 2018

BNTC: Benitec Biopharma Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	333.98
Enterprise Value ($M)	255.69
Book Value ($M)	75.94
Book Value / Share	2.98
Price / Book	4.40
NCAV ($M)	75.59
NCAV / Share	2.96
Price / NCAV	4.42

Profitability (mra)
Return on Invested Capital (ROIC)	-0.28
Return on Assets (ROA)	-1.43
Return on Equity (ROE)	-1.86

Liquidity (mrq)
Quick Ratio	25.48
Current Ratio	25.48

Balance Sheet (mrq) ($M)
Current Assets	78.71
Assets	79.07
Liabilities	3.13
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
5 days ago	13G/A	Franklin Resources Inc	16.30	-1.75
03-28	13D/A	Suvretta Capital Management, Llc	49.90	9.03
02-14	13G/A	Janus Henderson Group Plc	11.30	-2.82
02-13	13G/A	HBM Healthcare Investments (Cayman) Ltd.	4.50	0.00
11-14	13G	Nantahala Capital Management, LLC	9.65

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-05-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P
2025-02-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-05-13	7,204	33,039	21.80
2025-05-12	2,122	35,267	6.02
2025-05-09	7,068	43,230	16.35
2025-05-08	961	17,307	5.55
(click for more detail)

Similar Companies
BGM – BGM Group Ltd.	BIVI – BioVie Inc.
BMRA – Biomerica, Inc.	BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited

Financial data and stock pages provided by
Fintel.io

Related